Armata receives $3.7 million more from the U.S. Department of War for AP-SA02 Phase 3

Armata Pharmaceuticals has received an additional $3.7 million in non-dilutive funds from the U.S. Department of War to support the Phase 3 programme of AP-SA02, its phage cocktail for complicated Staphylococcus aureus bacteremia. It is the first funding received specifically for Phase 3 execution under a previously announced award made through the Medical Technology Enterprise Consortium, and brings cumulative Department of War funding under that award to approximately $32.4 million.